Cargando…

Clinical impact of [(18)F]flutemetamol PET among memory clinic patients with an unclear diagnosis

PURPOSE: To investigate the impact of amyloid PET with [(18)F]flutemetamol on diagnosis and treatment management in a cohort of patients attending a tertiary memory clinic in whom, despite extensive cognitive assessment including neuropsychological testing, structural imaging, CSF biomarker analysis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Leuzy, Antoine, Savitcheva, Irina, Chiotis, Konstantinos, Lilja, Johan, Andersen, Pia, Bogdanovic, Nenad, Jelic, Vesna, Nordberg, Agneta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2019
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6486908/ https://www.ncbi.nlm.nih.gov/pubmed/30915522 http://dx.doi.org/10.1007/s00259-019-04297-5

Ejemplares similares

Spatial Normalization of (18)F-Flutemetamol PET Images Using an Adaptive Principal-Component Template
por: Lilja, Johan, et al.
Publicado: (2019)

Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging
por: Chiotis, Konstantinos, et al.
Publicado: (2015)

Imaging in-vivo tau pathology in Alzheimer’s disease with THK5317 PET in a multimodal paradigm
por: Chiotis, Konstantinos, et al.
Publicado: (2016)

Regional Disconnection in Alzheimer Dementia and Amyloid-Positive Mild Cognitive Impairment: Association Between EEG Functional Connectivity and Brain Glucose Metabolism
por: Smailovic, Una, et al.
Publicado: (2020)

Tau PET imaging: present and future directions
por: Saint-Aubert, Laure, et al.
Publicado: (2017)

Optimal timing of tau pathology imaging and automatic extraction of a reference region using dynamic [(18)F]THK5317 PET
por: Jonasson, My, et al.
Publicado: (2019)

Tau PET imaging in neurodegenerative tauopathies—still a challenge
por: Leuzy, Antoine, et al.
Publicado: (2019)

A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [(18)F]flutemetamol amyloid PET images
por: Bucci, Marco, et al.
Publicado: (2021)

[(18)F]THK5317 imaging as a tool for predicting prospective cognitive decline in Alzheimer’s disease
por: Chiotis, Konstantinos, et al.
Publicado: (2020)

Clinical impact of (18)F-FDG-PET among memory clinic patients with uncertain diagnosis
por: Perini, Giulia, et al.
Publicado: (2020)

Tau positron emission tomography imaging in tauopathies: The added hurdle of off-target binding
por: Lemoine, Laetitia, et al.
Publicado: (2018)

Alzheimer’s disease profiled by fluid and imaging markers: tau PET best predicts cognitive decline
por: Bucci, Marco, et al.
Publicado: (2021)

Longitudinal tau and metabolic PET imaging in relation to novel CSF tau measures in Alzheimer’s disease
por: Leuzy, Antoine, et al.
Publicado: (2019)

Clinical significance of focal ß-amyloid deposition measured by (18)F-flutemetamol PET
por: Kim, Si Eun, et al.
Publicado: (2020)

Estimation of amyloid distribution by [(18)F]flutemetamol PET predicts the neuropathological phase of amyloid β-protein deposition
por: Thal, Dietmar Rudolf, et al.
Publicado: (2018)

Software compatibility analysis for quantitative measures of [(18)F]flutemetamol amyloid PET burden in mild cognitive impairment
por: Pemberton, Hugh G., et al.
Publicado: (2023)

Profiling of plasma biomarkers in the context of memory assessment in a tertiary memory clinic
por: Bucci, Marco, et al.
Publicado: (2023)

Is Amyloid Burden Measured by (18)F-Flutemetamol PET Associated with Progression in Clinical Alzheimer’s Disease?
por: Müller, Ebba Gløersen, et al.
Publicado: (2022)

Diagnostic impact of [(18)F]flutemetamol PET in early-onset dementia
por: Zwan, Marissa D., et al.
Publicado: (2017)

Amyloid-Targeting PET Tracer [(18)F]Flutemetamol Accumulates in Atherosclerotic Plaques
por: Hellberg, Sanna, et al.
Publicado: (2019)

Clinical outcomes up to 9 years after [(18)F]flutemetamol amyloid-PET in a symptomatic memory clinic population
por: Collij, Lyduine E., et al.
Publicado: (2023)

Initial Physician Experience with [(18)F]Flutemetamol Amyloid PET Imaging Following Availability for Routine Clinical Use in Japan
por: Hattori, Naoya, et al.
Publicado: (2020)

Assessment of Tau Pathology as Measured by (18)F-THK5317 and (18)F-Flortaucipir PET and Their Relation to Brain Atrophy and Cognition in Alzheimer’s Disease
por: Colato, Elisa, et al.
Publicado: (2021)

Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid
por: Rosenberg, Anna, et al.
Publicado: (2019)

Early-phase (18)F-FP-CIT and (18)F-flutemetamol PET were significantly correlated
por: An, Young-Sil, et al.
Publicado: (2021)

A Case of Early Onset Alzheimer's Disease Diagnosed by (18)F Flutemetamol PET Image
por: Kim, Jeong-Hoon, et al.
Publicado: (2018)

Cross-interaction of tau PET tracers with monoamine oxidase B: evidence from in silico modelling and in vivo imaging
por: Murugan, N. Arul, et al.
Publicado: (2019)

Optimized dual-time-window protocols for quantitative [(18)F]flutemetamol and [(18)F]florbetaben PET studies
por: Heeman, Fiona, et al.
Publicado: (2019)

Post-mortem histopathology underlying β-amyloid PET imaging following flutemetamol F 18 injection
por: Ikonomovic, Milos D., et al.
Publicado: (2016)

Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [(18)F]-Flutemetamol PET Scan Result
por: Westwood, Sarah, et al.
Publicado: (2018)

Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework
por: Chiotis, Konstantinos, et al.
Publicado: (2021)

Appropriate reference region selection of (18)F-florbetaben and (18)F-flutemetamol beta-amyloid PET expressed in Centiloid
por: Cho, Soo Hyun, et al.
Publicado: (2020)

Assessment of perfusion deficit with early phases of [(18)F]PI-2620 tau-PET versus [(18)F]flutemetamol-amyloid-PET recordings
por: Völter, Friederike, et al.
Publicado: (2022)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

(18)F-flutemetamol positron emission tomography in cardiac amyloidosis
por: Papathanasiou, Maria, et al.
Publicado: (2020)

Regional tau deposition measured by [(18)F]THK5317 positron emission tomography is associated to cognition via glucose metabolism in Alzheimer’s disease
por: Saint-Aubert, Laure, et al.
Publicado: (2016)

Discriminative binding of tau PET tracers PI2620, MK6240 and RO948 in Alzheimer’s disease, corticobasal degeneration and progressive supranuclear palsy brains
por: Malarte, Mona-Lisa, et al.
Publicado: (2022)

Infrequent false positive [(18)F]flutemetamol PET signal is resolved by combined histological assessment of neuritic and diffuse plaques
por: Ikonomovic, Milos D., et al.
Publicado: (2018)

Validation of an electronic image reader training programme for interpretation of [(18)F]flutemetamol β-amyloid PET brain images
por: Buckley, Christopher J., et al.
Publicado: (2017)

Quantitative Evaluation of (18)F-Flutemetamol PET in Patients With Cognitive Impairment and Suspected Alzheimer's Disease: A Multicenter Study
por: Matsuda, Hiroshi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_htrdcpjjv8bvtdnfuqpldr6mfa